CIK 0001761612 · Non-accelerated filer<br>Smaller reporting company
BICYCLE THERAPEUTICS PLC
Sign in to watch- Ticker
- BCYC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 011441223261503
- Business address
- BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
- Former names
- BICYCLE THERAPEUTICS Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $64,039
- in 7 filings, $7K under 10b5-1 plans
Net −$64,039. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Lee Kevin −$27K CHIEF EXECUTIVE OFFICER sold 1% of stake
- Swanton Robert Charles −$12K Director sold 18% of stake
- Skynner Michael −$9K CHIEF SCIENTIFIC OFFICER sold 2% of stake
- Perry Jennifer Scott −$7K Chief Operating Officer sold 2% of stake
- Hannay Michael Charles Ferguson −$6K CHIEF PROD & SUPPLY CHAIN OFF sold 2% of stake
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-29 | Kalowski Lee President and CFO | Sale | −300 | $32.81 | $10K | 0 |
| 2021-07-29 | Kalowski Lee President and CFO | Option exercise · Stock Option (Right to Buy) | −12,500 | 67,274 | ||
| 2021-07-26 | Lee Kevin Chief Executive Officer | Option exercise | +100 | $14.00 | $1K | 245,185 |
| 2021-07-26 | Lee Kevin Chief Executive Officer | Sale | −100 | $36.00 | $4K | 245,085 |
| 2021-07-26 | Lee Kevin Chief Executive Officer | Option exercise · Stock Option (right to buy) | −100 | 341,370 | ||
| 2021-07-23 | Lee Kevin Chief Executive Officer | Option exercise | +4,782 | $14.00 | $67K | 249,867 |
| 2021-07-23 | Lee Kevin Chief Executive Officer | Sale | −4,782 | $36.02 | $172K | 245,085 |
| 2021-07-23 | Lee Kevin Chief Executive Officer | Option exercise · Stock Option (right to buy) | −4,782 | 341,470 | ||
| 2021-07-16 | Lee Kevin Chief Executive Officer | Option exercise | +609 | $14.00 | $9K | 245,694 |
| 2021-07-16 | Lee Kevin Chief Executive Officer | Sale | −609 | $34.00 | $21K | 245,085 |
| 2021-07-16 | Lee Kevin Chief Executive Officer | Option exercise · Stock Option (right to buy) | −609 | 346,252 | ||
| 2021-07-15 | Lee Kevin Chief Executive Officer | Option exercise | +21,970 | $14.00 | $308K | 267,055 |
| 2021-07-15 | Lee Kevin Chief Executive Officer | Sale | −21,970 | $34.28 | $753K | 245,085 |
| 2021-07-15 | Lee Kevin Chief Executive Officer | Option exercise · Stock Option (right to buy) | −21,970 | 346,861 | ||
| 2021-07-14 | BINGHAM KATE Director | Sale | −43,378 | $34.01 | $1.5M | 1,831,671 |
| 2021-07-14 | BINGHAM KATE Director | Sale | −917 | $34.01 | $31K | 38,708 |
| 2021-07-14 | Keen Nicholas Chief Scientific Officer | Sale | −10,000 | $35.00 | $350K | 18,321 |
| 2021-07-14 | BINGHAM KATE Director | Sale | −43,378 | $34.01 | $1.5M | 1,831,671 |
| 2021-07-14 | BINGHAM KATE Director | Sale | −917 | $34.01 | $31K | 38,708 |
| 2021-07-14 | Lee Kevin Chief Executive Officer | Option exercise | +8,331 | $14.00 | $117K | 259,550 |
Page 21 of 26 · 520 trades